Cover Image

Visudyne (黃斑部水腫·黃斑部病變治療藥) - 2023年前的預測與市場分析

Visudyne (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 325954
出版日期 內容資訊 英文 78 Pages
Back to Top
Visudyne (黃斑部水腫·黃斑部病變治療藥) - 2023年前的預測與市場分析 Visudyne (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023
出版日期: 2014年10月31日 內容資訊: 英文 78 Pages



本報告提供黃斑部水腫及黃斑部病變治療藥物──Visudyne (verteporfin) 之相關調查,提供您黃斑部水腫及黃斑部病變概要和治療藥的競爭趨勢,產品資訊,銷售額預測等資訊。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 黃斑部病變 概要
    • 病因與病理學
    • 分類
    • 症狀與診斷
  • 黃斑部水腫 概要
    • 病因與病理學
    • 分類
    • 症狀與診斷

第4章 疾病的管理

  • 疾病和治療概要
    • 黃斑部水腫的診斷
    • 黃斑部病變的診斷
    • 治療指南主要的處方藥
    • 臨床診療

第5章 競爭評估

  • 概要

第6章 Visudyne (verteporfin)

  • 概要
  • 有效性 - 黃斑部病變
  • 安全性
  • SWOT分析
  • 預測

第7章 附錄

Product Code: GDHC483DFR

Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). Age-related macular degeneration (AMD) is a painless eye condition which leads to gradual, irreversible, loss of central vision, and is one of the leading causes of blindness among people aged 50 and over in the developed world. Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years. The launch of wet AMD adjunctive therapies will also see a significant change in the treatment of AMD patients and have a positive impact on the market growth.

Visudyne (verteporfin) is a photosensitizer molecule that was co-developed by QLT PhotoTherapeutics and Novartis Pharma AG for use in a two-step procedure involving the use of a non-thermal laser light, known as PDT. It was initially approved by the FDA in April 2000 for the treatment of patients with predominantly classical subfoveal CNV due to AMD.


  • Overview of Macular Edema and Macular Degeneration, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Visudyne including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Visudyne for the top seven countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return.
  • Stay ahead of the competition by understanding the changing competitive landscape for Macular Edema and Macular Degeneration.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
  • Make more informed business decisions from insightful and in-depth analysis of Visudyne performance.
  • Obtain sales forecast for Visudyne from 2013-2023 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan).

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Related Reports

3. Disease Overview

  • 3.1. Macular Degeneration Overview
    • 3.1.1. Etiology and Pathophysiology
    • 3.1.2. Classification
    • 3.1.3. Symptoms and Diagnosis
  • 3.2. Macular Edema Overview
    • 3.2.1. Etiology and Pathophysiology
    • 3.2.2. Classification
    • 3.2.3. Symptoms and Diagnosis

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Macular Edema Diagnosis
    • 4.1.2. Macular Degeneration Diagnosis
    • 4.1.3. Treatment Guidelines and Leading Prescribed Drugs
    • 4.1.4. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview

6. Visudyne (verteporfin)

  • 6.1. Overview
  • 6.2. Efficacy - Macular Degeneration
  • 6.3. Safety

6.4. SWOT Analysis

  • 6.5. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosed ME and AMD Patients
    • 7.4.2. Percentage of Drug-Treated Patients
    • 7.4.3. General Pricing Assumptions
    • 7.4.4. Individual Drug Assumptions
  • 7.5. Primary Research - KOLs Interviewed for this Report
  • 7.6. Primary Research - High-Prescribers Survey
  • 7.7. About the Authors
    • 7.7.1. Analyst
    • 7.7.2. Therapy Area Director
    • 7.7.3. Global Head of Healthcare
  • 7.8. About GlobalData
  • 7.9. Disclaimer

List of Tables

  • Table 1: ARM System Classification of AMD
  • Table 2: Symptoms of AMD
  • Table 3: National and International Treatment Guidelines for ME and AMD
  • Table 4: Most Prescribed Drugs for ME and AMD in the Global Markets, 2013
  • Table 5: Leading Treatments for ME and AMD, 2014
  • Table 6: Product Profile - Visudyne
  • Table 7: Visudyne SWOT Analysis, 2014
  • Table 8: Global Sales Forecast ($m) for Visudyne, 2013-2023
  • Table 9: Surveyed High-Prescribing Physicians (Non-KOLs), by Country

List of Figures

  • Figure 1: Anatomy of the Eye and Macula
  • Figure 2: Amsler Grid viewed by Patient with Normal Vision and with wAMD
  • Figure 3: Color Fundus Photographs of Dry and Wet AMD
  • Figure 4: FAF Imaging of GA
  • Figure 5: Imaging of wAMD
  • Figure 6: CMT in DME
  • Figure 7: RVOs (BRVO and CRVO) on an FA
  • Figure 8: Increased CRT in ME-RVO
  • Figure 9: ME Clinical Treatment Flowchart
  • Figure 10: AMD Clinical Treatment Flowchart
Back to Top